Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK2 | O96017 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 2/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.37 |
| ▸ | PDE8B | O95263 | 1/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6929664 | 0.85 | CHEK2 (0.42) | CHEK2KDM1APRMT5ATMTRPV1 | |
| SCHEMBL19665712 | 0.76 | ALDH1A1 (0.42) | CHEK2ATMTRPV1NPC1 | |
| SCHEMBL8293870 | 0.74 | ATM (0.40) | CHEK2KDM1APRMT5ATMTRPV1 | |
| SCHEMBL19665738 | 0.74 | PRKCQ (0.40) | CHEK2TRPV1NPC1 | |
| SCHEMBL18285457 | 0.73 | OPRD1 (0.42) | KDM1APRMT5GPR119TRPV1NPC1 | |
| SCHEMBL18285458 | 0.73 | OPRD1 (0.42) | KDM1APRMT5GPR119TRPV1NPC1 | |
| SCHEMBL5481717 | 0.72 | ATM (0.39) | CHEK2KDM1APRMT5ATMTRPV1 | |
| SCHEMBL21611438 | 0.72 | GPR119 (0.45) | CHEK2PRMT5GPR119PDE8B | |
| SCHEMBL5483634 | 0.72 | ATM (0.38) | CHEK2KDM1APRMT5ATMTRPV1 | |
| SCHEMBL8406910 | 0.71 | GPR119 (0.41) | GPR119NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030225131-A1 | Thrombin inhibitors | BURGEY CHRISTOPHER S (US) | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225131-A1 | Thrombin inhibitors | TFPI, SERPINC1, PLAT | CHEK2 4055/4885KDM1A 2931/4885PRMT5 903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.